spacer
home > ict > autumn 2009 > comparator supply: the way forward
PUBLICATIONS
International Clinical Trials

Comparator Supply: The Way Forward

 

In order to obtain marketing authorisation for a new medicinal product, the trial sponsors must test against the current market leader: more commonly known as a comparator drug. Clinical trials must demonstrate that the innovative drug is effective and safe for patient use before it is approved, and rigorous testing under trial conditions is the only way to prove this. In order to source these products successfully, one needs to have a partner competent at procurement, with an in-depth knowledge of the pharmaceutical marketplace within the EU, North America and the rest of the world. Many sponsors and their agents believe this is the easiest part of the clinical trial, and do not plan for it from the outset. This article aims to dispel some of the confusion surrounding the process of comparator procurement, and reveals some of the considerations that need to be taken into account as part of the clinical trial protocol.

Fortunately, it is accepted within the pharmaceutical industry that, in order to bring innovative medications to market, each trial sponsor needs to be able to access comparator drugs for use in clinical trials, and there is general agreement throughout the industry that manufacturers will cooperate with requests for their product to be made available for such use.

EARLY ACTION

Requests for comparator drugs are typically significant in quantity, and are required to be from a single batch, supplied with supporting paperwork such as a Certificate of Analysis, MSDS, TSE/BSE statements and pedigree documentation. The amount of comparator drug requested will reflect the number of patients recruited to take part in the trial, while the provision of product from a single batch seeks to ensure continuity of results. Samples may be requested ahead of a larger order to enable an evaluation of the product and its packaging. Supply from a single batch will allow any relabelling or repackaging procedures to be centralised, ideally reducing time, cost and effort. The expiry date of the product will also be scrutinised to ensure that the comparator lasts until the end of the trial. For those products with a relatively short shelf life, one needs to plan for regular resupply during the trial’s duration. To ensure that all these factors are taken into account, a planning team must take early action with the comparator provider to ensure that the trial takes place on time and within budget, and that there are no supply shortfalls during the lifespan of the trial.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
As founder of ADAllen Pharma, David Allen has played a fundamental role in the company’s continued success, overseeing its assured progress from a national operation to a major international supplier. A Fellow of the Royal Pharmaceutical Society of Great Britain, where he has served as both Vice President and Treasurer, David has chaired a number of standing committees and is a leading voice for the enforcement of high professional standards within the industry.
spacer
David Allen
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

EXTERNAL COMMUNICATION, 24 October 2019, Copenhagen, Denmark PRESS RELEASE – FLYPHARMA CONFERENCE EUROPE 2019

For its fifth annual Europe conference, FlyPharma chose Copenhagen as its host city to address the latest supply chain challenges and industry best practices, putting together a global audience of (bio)pharma and logistics professionals. The two-day conference (22-23 October 2019) aimed to discuss the collaboration and growth within Scandinavia, with a special focus on women in pharmaceutical logistics and an exploration of the industry’s digitalisation and innovation.
More info >>

White Papers

Clinical Trials in Russia Orange Paper: Summary of Year 2013

Synergy Research Group

Russia remains a very popular geography for local, regional, and global pharmaceutical companies to conduct clinical trials. Sponsors mention the following reasons for conducting studies in Russia: 1. Fast patient enrollment due to the centralized medical infrastructure. 2. Nearly 100% patient retention 3. GCP trained and certified Investigative Sites generating high quality data 4. Low cost: Average per patient cost is 60% to 70% below US and European prices due to the low cost of Investigators and the high concentration of patients in therapeutically aligned medical centers
More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement